From the School of Nutrition Sciences and Food Technology (Moludi), Kermanshah University of Medical Sciences, Kermanshah, Iran; Nutrition Research Center, Faculty of Nutrition (Alizadeh, Davari), Tabriz University of Medical Sciences, Tabriz, Iran; and Department of Cardiology, Shohada Hospital (Mohammadzad), Urmia University of Medical Sciences, Urmia, Iran.
Psychosom Med. 2019 Nov/Dec;81(9):770-777. doi: 10.1097/PSY.0000000000000749.
Evidence indicates that probiotic supplements may improve or prevent depression. Little is known about the effects of probiotic supplementation on symptoms of depression and quality of life (QOL) in patients with myocardial infarction (MI).
This randomized, double-blind, and placebo-controlled clinical trial was performed in 44 patients with a recent diagnosis of MI who underwent percutaneous coronary intervention. Patients were randomly assigned to receive either capsules containing 1.6 × 10 colony-forming units of Lactobacillus rhamnosus capsules with their lunch (the active intervention group) or capsules that contained maltodextrin (the placebo control group) for 12 weeks. The Beck Depression Inventory, QOL, and biomarkers of oxidative stress (serum total antioxidant capacity), and malondialdehyde), and high-sensitivity C-reactive protein (hs-CRP) as inflammation marker were assessed. These measures were obtained at baseline and at 12 weeks' follow-up.
The total Beck Depression Inventory score decreased significantly in patients who received probiotic supplements compared with the placebo group (-5.57 [6.1] versus -0.51 [2.8], p = .045). Improvements in the mean QOL score were also stronger in the probiotic versus the placebo group (23.6 [39.1] versus 0.44 [42.6], p = .023). In addition, increases in total antioxidant capacity (93.7 [88.4] versus 27.54 [64.7] mmol/l, p = .009) and decreases in malondialdehyde (-40.7 [63.73] versus -4.2 [67.6] nmol/ml, p = .033) and high-sensitivity C-reactive protein (-1.74 [0.70] versus 0.67 [1.27] mg/l, p = .040) levels were stronger in patients receiving probiotic supplementation than the placebo group.
These data provide preliminary evidence that probiotic supplementation in patients with percutaneous coronary intervention post-MI has beneficial effects on depressive symptoms and markers of oxidative stress and inflammation. Multicenter studies with larger sample sizes are needed to replicate these findings and identify patient subgroups with the most benefit from probiotic supplementation.
www.irct.ir identifier: IRCT20121028011288N15.
有证据表明，益生菌补充剂可能改善或预防抑郁。但对于益生菌补充剂对心肌梗死（MI）患者的抑郁症状和生活质量（QOL）的影响知之甚少。
这项随机、双盲、安慰剂对照的临床试验在 44 名近期诊断为 MI 并接受经皮冠状动脉介入治疗的患者中进行。患者被随机分配接受含有 1.6×10 个菌落形成单位的鼠李糖乳杆菌胶囊和午餐一起服用的胶囊（活性干预组）或含有麦芽糊精的胶囊（安慰剂对照组），为期 12 周。采用贝克抑郁量表、生活质量、氧化应激生物标志物（血清总抗氧化能力）和丙二醛）以及高敏 C 反应蛋白（hs-CRP）作为炎症标志物。这些指标在基线和 12 周随访时进行评估。
与安慰剂组相比，接受益生菌补充剂的患者的总贝克抑郁量表评分显著下降（-5.57[6.1]与-0.51[2.8]，p=0.045）。益生菌组的平均生活质量评分也有更强的改善（23.6[39.1]与 0.44[42.6]，p=0.023）。此外，总抗氧化能力的增加（93.7[88.4]与 27.54[64.7]mmol/l，p=0.009）和丙二醛的减少（-40.7[63.73]与-4.2[67.6]nmol/ml，p=0.033）以及高敏 C 反应蛋白的减少（-1.74[0.70]与 0.67[1.27]mg/l，p=0.040）在接受益生菌补充剂的患者中比安慰剂组更强。
这些数据初步表明，心肌梗死后经皮冠状动脉介入治疗的患者补充益生菌对抑郁症状和氧化应激及炎症标志物有有益影响。需要更大样本量的多中心研究来复制这些发现，并确定从益生菌补充中获益最多的患者亚组。
www.irct.ir 标识符：IRCT20121028011288N15。
